VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Shigella sonnei virG/senA/senB/msbB2 mutant vaccine
Vaccine Information
  • Vaccine Name: Shigella sonnei virG/senA/senB/msbB2 mutant vaccine
  • Target Pathogen: Shigella
  • Target Disease: Shigellosis
  • Product Name: WRSs3
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Guinea pig
  • virG gene engineering:
    • Type: Gene mutation
    • Description: This virG/senA/senB/msbB2 mutant is from Shigella sonnei (Barnoy et al., 2010).
    • Detailed Gene Information: Click Here.
  • senA gene engineering:
    • Type: Gene mutation
    • Description: This virG/senA/senB/msbB2 mutant is from Shigella sonnei (Barnoy et al., 2010).
    • Detailed Gene Information: Click Here.
  • senB gene engineering:
    • Type: Gene mutation
    • Description: This virG/senA/senB/msbB2 mutant is from Shigella sonnei (Barnoy et al., 2010).
    • Detailed Gene Information: Click Here.
  • msbB2 gene engineering:
    • Type: Gene mutation
    • Description: This virG/senA/senB/msbB2 mutant is from Shigella sonnei (Barnoy et al., 2010).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral immunization
Host Response

Guinea pig Response

  • Persistence: A virG, senA, senB, and msbB2 mutant is attenuated in guinea pigs (Barnoy et al., 2010).
  • Efficacy: A virG, senA, senB, and msbB2 mutant induces protection in guinea pigs from challenge with wild type Shigella sonnei (Barnoy et al., 2010).
  • Host IgA response
    • Description: Serum GMTs of LPS-specific and Invaplex-specific IgG and IgA were very similar across the three vaccine candidates, indicating that WRSs2 and WRSs3 elicited comparable levels of humoral immune responses in guinea pigs as WRSS1. Antibodies were measured days 0, 7, and 14 after inoculation as well as 2 weeks after challenge. Antibody levels increased greatly between days 0 and 28 (Barnoy et al., 2010).
    • Detailed Gene Information: Click Here.
  • Host IgG Fc receptor II response
    • Description: Serum GMTs of LPS-specific and Invaplex-specific IgG and IgA were very similar across the three vaccine candidates, indicating that WRSs2 and WRSs3 elicited comparable levels of humoral immune responses in guinea pigs as WRSS1. Antibodies were measured days 0, 7, and 14 after inoculation as well as 2 weeks after challenge. Antibody levels increased greatly between days 0 and 28 (Barnoy et al., 2010).
    • Detailed Gene Information: Click Here.
References
Barnoy et al., 2010: Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine. 2010; 28(6); 1642-1654. [PubMed: 19932216].